An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

NCT00235300 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Cadaveric Donor Renal Transplantation
Acute Renal Allograft Rejection
Induction Therapy

Interventions

BIOLOGICAL: Thymoglobulin [Anti-thymocyte Globulin (rabbit)]
DRUG: Simulect (basliximab)

Sponsor

Genzyme, a Sanofi Company